While the former Biden administration showcased the Inflation Reduction Act as a key victory in the fight over high drug ...

The Economic Survey 2024-25 says on a global pedestal, India has successfully established itself as one of the top 20 medical ...

There is a need to focus on innovation, new drug development and biopharmaceuticals as spending on research and development ...

New Delhi: Drug major Glenmark Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under ...

Economic Survey 2025 calls for systematic deregulation, focus on R&D: Our Bureau, New Delhi Friday, January 31, 2025, 15:30 Hrs [IST] Projecting a growth of around 6.3 to 6.8 per ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the progress of the U.S. commercial launch of Ryoncil ® ...

JMP Securities maintained a positive outlook on Kalvista Pharmaceuticals Inc (NASDAQ:KALV), reiterating a Market Outperform ...

The Economic Survey 2024-25 emphasises the need for increased innovation, new drug development, and biopharmaceutical ...

JMP Securities initiated coverage of KalVista (KALV) with an Outperform rating and $19 price target KalVista is developing sebetralstat, a ...

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on KalVista Pharmaceuticals (KALV).Invest with Confidence: ...